Personalis Basic EPS 2018-2024 | PSNL
Personalis basic eps from 2018 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
Personalis Annual Basic EPS |
2023 |
$-2.25 |
2022 |
$-2.48 |
2021 |
$-1.49 |
2020 |
$-1.20 |
2019 |
$-1.39 |
2018 |
$-6.49 |
2017 |
$-7.78 |
Personalis Quarterly Basic EPS |
2024-06-30 |
$-0.24 |
2024-03-31 |
$-0.26 |
2023-12-31 |
$-0.54 |
2023-09-30 |
$-0.60 |
2023-06-30 |
$-0.50 |
2023-03-31 |
$-0.61 |
2022-12-31 |
$-0.67 |
2022-09-30 |
$-0.58 |
2022-06-30 |
$-0.60 |
2022-03-31 |
$-0.63 |
2021-12-31 |
$-0.46 |
2021-09-30 |
$-0.40 |
2021-06-30 |
$-0.34 |
2021-03-31 |
$-0.29 |
2020-12-31 |
$-0.35 |
2020-09-30 |
$-0.27 |
2020-06-30 |
$-0.29 |
2020-03-31 |
$-0.29 |
2019-12-31 |
$1.56 |
2019-09-30 |
$-0.22 |
2019-06-30 |
$-0.89 |
2019-03-31 |
$-1.84 |
2018-12-31 |
|
2018-09-30 |
$-1.19 |
2018-06-30 |
$-2.39 |
2017-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.278B |
$0.073B |
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|